Non-Hodgkin's Lymphoma News

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

FDA Approves Aliqopa for Relapsed Follicular Lymphoma (May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who... Continue Reading

FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma (May 21, 2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell... Continue Reading

Keytruda Effective in Patients with Relapsed or Refractory Lymphoma (January 23, 2018)

CancerConnect News: Findings from the KEYNOTE-170 clinical trial Presented at the 59th American Society of Hematology (ASH) Annual Meeting suggest that the novel immunotherapy medication keytruda® (pembrolizumab) represents a new treatment option for... Continue Reading

FDA approves Gazyva for previously untreated follicular lymphoma (January 11, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment... Continue Reading

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) (November 15, 2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer (October 23, 2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior... Continue Reading

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

Latest Non-Hodgkin's Lymphoma News By Stage


Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

Follicular Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

More Follicular Lymphoma

Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

Indolent/Low Grade Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Indolent/Low Grade Non-Hodgkin's Lymphoma

Mantle Cell Non-Hodgkin's Lymphoma

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (May 31, 2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

More Mantle Cell Non-Hodgkin's Lymphoma

Recurrent Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Recurrent Non-Hodgkin's Lymphoma

Screening/Prevention Non-Hodgkin's Lymphoma

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Non-Hodgkin's Lymphoma

T-Cell Non-Hodgkin's Lymphoma

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

More T-Cell Non-Hodgkin's Lymphoma